drug · small molecule
savolitinib
Phase 2updated 5mo agoby $AZN ASTRAZENECA PLC🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 9 investigational indications.
indications
indications
NSCLC
targets
Hepatocyte growth factor receptor
all catalysts(0)
nothing on the calendar yet
Trials studying savolitinib
- phase3Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
- phase2A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
- phase2Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
- phase2Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
- phase3Savolitinib vs. Sunitinib in MET-driven PRCC.
- phase3Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- phase1A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers
- phase3Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
News(1)
- WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlightThe year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.biopharma_dive · 15d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that